Skip to main content
. Author manuscript; available in PMC: 2023 Nov 27.
Published in final edited form as: N Engl J Med. 2019 Nov 27;381(24):2293–2303. doi: 10.1056/NEJMoa1910993

Table 4.

Multivariate Logistic-Regression Analyses for Death at 28 Days in the 371 Patients Who Had Data Available for All Variables.

Variable Odds Ratio (95% CI)
Assignment to remdesivir vs. ZMapp 0.99 (0.46–2.14)
Assignment to MAb114 vs. ZMapp 0.24 (0.10–0.61)
Assignment to REGN-EB3 vs. ZMapp 0.21 (0.08–0.53)
Duration of symptoms before admission to treatment center, per each additional day 1.12 (1.00–1.24)
Baseline nucleoprotein Ct value per 1-unit increase 0.67 (0.59–0.76)
Years of age per 1 yr increase 1.02 (1.00–1.04)
Creatinine level per 1 mg/dl increase 1.36 (1.18–1.58)
AST level per 100 U/liter increase 1.00 (0.92–1.07)
ALT level per 100 U/liter increase 0.96 (0.79–1.17)
Patient-reported vaccination, yes vs. no 0.47 (0.21–1.01)